about
Increasing the risk of spontaneous abortion and major malformations in newborns following use of serotonin reuptake inhibitors during pregnancy: A systematic review and updated meta-analysisA meta-analysis of the relationship between antidepressant use in pregnancy and the risk of preterm birth and low birth weightMaternal depressive symptoms, depression, and psychiatric medication use in relation to risk of preterm deliveryElevated midpregnancy corticotropin-releasing hormone is associated with prenatal, but not postpartum, maternal depressionAntidepressants, anxiolytics, and hypnotics in pregnancy and lactationA patient decision aid for antidepressant use in pregnancy: study protocol for a randomized controlled trial.Antidepressant use in pregnancy: a critical review focused on risks and controversiesSelective serotonin reuptake inhibitor (SSRI) use during pregnancy and risk of preterm birth: a systematic review and meta-analysis.Monoamine-sensitive developmental periods impacting adult emotional and cognitive behaviors.Prenatal antidepressant exposure: clinical and preclinical findings.Fetal effects of psychoactive drugsIncreased risk of severe congenital heart defects in offspring exposed to selective serotonin-reuptake inhibitors in early pregnancy--an epidemiological study using validated EUROCAT data.Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data.Prepregnancy depressive mood and preterm birth in black and white women: findings from the CARDIA Study.Risk of preterm delivery and other adverse perinatal outcomes in relation to maternal use of psychotropic medications during pregnancy.Preschool outcomes following prenatal serotonin reuptake inhibitor exposure: differences in language and behavior, but not cognitive function.Antidepressant use in pregnant and postpartum womenExposed or not exposed? Exploring exposure classification in studies using administrative data to investigate outcomes following medication use during pregnancy.Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: evidence from in vitro and animal-based studiesUse of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysisLength of prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants: effects on neonatal adaptation and psychomotor development.Treatment of nonpsychotic major depression during pregnancy: patient safety and challengesTranscranial direct current stimulation (tDCS) for treatment of major depression during pregnancy: study protocol for a pilot randomized controlled trialBehavioral and developmental changes in rats with prenatal exposure of mirtazapine.A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restrictionEvidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines.Safety of newer antidepressants in pregnancy.Paroxetine and neonatal withdrawal syndrome.The safety of antidepressant drugs during pregnancy.Depression during pregnancyPrevalence of antidepressant use during pregnancy in Denmark, a nation-wide cohort studyPresence of depressive symptoms during early pregnancy and the risk of preterm delivery: a prospective cohort study.Treatment with selective serotonin reuptake inhibitors during pregnancy: deceleration of weight gain because of depression or drug?Effect of exposure to selective serotonin reuptake inhibitors in utero on fetal growth: potential role for the IGF-I and HPA axes.The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists.Fluoxetine induces proliferation and inhibits differentiation of hypothalamic neuroprogenitor cells in vitroPreterm birth and antidepressant medication use during pregnancy: a systematic review and meta-analysis.Impact of physician counseling and perception of teratogenic risks: a survey of 96 nonpregnant women with anxietyAntidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction.Newborn neurobehavioral patterns are differentially related to prenatal maternal major depressive disorder and serotonin reuptake inhibitor treatment
P2860
Q21198704-C11413A9-CCCB-4768-8FBF-4FA20BF4BC39Q24623163-53F74A5D-7876-450B-B04D-DF31B2F1E2DDQ24627027-6280F6BA-2ADE-44FC-A2AF-452C94AA41C9Q24654669-CD510DBA-16D4-4EBE-8C00-4FF1C7847655Q26795384-DC1EA8C5-2532-4A5E-B44A-CF55497F4F6DQ27334448-A897CD52-3CE8-450B-910E-AF892BA7B9B4Q28281407-EEBA8348-ADB7-44CD-8CA8-D3A0DF3497DBQ30244451-48C97005-575A-4B75-A4C9-E61AC98600EEQ30395001-395DF301-0FD8-4194-8DBC-3DCA019CA3CEQ30415540-6BF606FF-7B23-4F3F-B788-CB14E1DAA1B5Q30479705-82E4E180-FCD2-4BC9-8C02-99F1AE9A6517Q30855293-0B0E5843-37B9-4D7D-8BFB-276068506A70Q33521786-BE911013-A16C-43E7-8AA9-0171668C661AQ33775282-1B7BAF11-8EE0-4142-A2CF-A358F195650CQ33896573-F5CB168F-330B-4FA1-849D-2067DC8E0A16Q33907544-FD655E2F-89B0-4440-AD05-12DD4F09BDEBQ34068023-077FCC4B-FE7B-4536-B35E-76C85BB0C4F7Q34073546-7998AD65-3E05-4413-B220-5595D663C261Q34140313-5C0C2E52-49D4-4BBB-8F45-31E457D8D4FEQ34144128-1B9AFF72-E6BF-4E91-80DE-8BC6BA3D0C38Q34178991-D94C78B4-9E31-4251-972A-10804F7CAD36Q34237681-27A59C43-C412-4027-A0ED-2A6F6FFB5F88Q34255298-E8987190-A2B4-4DBB-9EF0-138BA81DB438Q34409959-732F9822-97AB-45B0-BAE4-8F09DD3E616CQ34514870-F2C09421-5461-4FA3-B354-128BCFDDBB2FQ34590507-3303BD1C-BF58-4AB2-9985-41258345835AQ34611697-2E4C786A-FFC3-422F-9D08-3D6BB2014E2BQ34618623-BC083375-55C1-46BF-91D6-43732163DF93Q34661348-E4AA1D26-525E-4D8A-93EE-FEE54E5538D6Q34682688-EBF7B403-3B8F-42BF-B548-83990B67D83BQ34702282-B457DF67-EB6E-4564-A7F9-4089DF346B19Q34864429-C5EABF35-689B-44F0-8AE2-4355588CDEEAQ34917706-5C4BD4A5-08EE-4254-8F67-3582F1BCFC89Q34956921-DC191F9F-7D28-4067-8638-FCC93B0C7D07Q34981937-B422DDD0-A0F8-4D1B-A3D9-ADEC6D5B778EQ35111996-752F42A7-CFCD-4405-AE3C-89190B2DAA72Q35132422-FB535A3E-717E-4877-BFC5-28A2D7B86208Q35252134-47BAE6D3-725F-4684-BA1D-312D89B2A6C4Q35506589-B1E73FDC-A328-438C-98AC-C033170F93FAQ35549316-7EDC0733-16FA-43DB-A8DD-2694620C299F
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Outcomes of prenatal antidepressant exposure.
@ast
Outcomes of prenatal antidepressant exposure.
@en
type
label
Outcomes of prenatal antidepressant exposure.
@ast
Outcomes of prenatal antidepressant exposure.
@en
prefLabel
Outcomes of prenatal antidepressant exposure.
@ast
Outcomes of prenatal antidepressant exposure.
@en
P2093
P1476
Outcomes of prenatal antidepressant exposure.
@en
P2093
Gregory E Simon
Michael L Cunningham
Robert L Davis
P304
P356
10.1176/APPI.AJP.159.12.2055
P407
P577
2002-12-01T00:00:00Z